NZ572366A - THE USE OF NICOTINE, ANALOGUES THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEREOF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORM - Google Patents
THE USE OF NICOTINE, ANALOGUES THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEREOF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORMInfo
- Publication number
- NZ572366A NZ572366A NZ572366A NZ57236606A NZ572366A NZ 572366 A NZ572366 A NZ 572366A NZ 572366 A NZ572366 A NZ 572366A NZ 57236606 A NZ57236606 A NZ 57236606A NZ 572366 A NZ572366 A NZ 572366A
- Authority
- NZ
- New Zealand
- Prior art keywords
- msh
- liver
- nicotine
- lung
- treatment
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title claims abstract description 23
- 229960002715 nicotine Drugs 0.000 title claims abstract description 23
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 title description 12
- 239000002243 precursor Substances 0.000 title description 10
- 230000000069 prophylactic effect Effects 0.000 title description 6
- 208000037273 Pathologic Processes Diseases 0.000 title description 2
- 230000006872 improvement Effects 0.000 title description 2
- WHNFPRLDDSXQCL-UHFFFAOYSA-N α-melanotropin Chemical compound C=1N=CNC=1CC(C(=O)NC(CC=1C=CC=CC=1)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)NC(CCCCN)C(=O)N1C(CCC1)C(=O)NC(C(C)C)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(NC(=O)C(CO)NC(C)=O)CC1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UHFFFAOYSA-N 0.000 title 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims abstract description 78
- 101710200814 Melanotropin alpha Proteins 0.000 claims abstract description 78
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims abstract description 78
- 210000004072 lung Anatomy 0.000 claims abstract description 25
- 208000028867 ischemia Diseases 0.000 claims abstract description 21
- 210000003734 kidney Anatomy 0.000 claims abstract description 18
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 206010038934 Retinopathy proliferative Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000003412 degenerative effect Effects 0.000 claims abstract description 5
- 230000006866 deterioration Effects 0.000 claims abstract description 5
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 230000002458 infectious effect Effects 0.000 claims abstract description 5
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 5
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 4
- 208000008589 Obesity Diseases 0.000 claims abstract description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 4
- 239000002158 endotoxin Substances 0.000 claims abstract description 4
- 230000007954 hypoxia Effects 0.000 claims abstract description 4
- 210000000936 intestine Anatomy 0.000 claims abstract description 4
- 235000020824 obesity Nutrition 0.000 claims abstract description 4
- 201000008482 osteoarthritis Diseases 0.000 claims abstract description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 3
- 206010020772 Hypertension Diseases 0.000 claims abstract description 3
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims abstract description 3
- 206010053476 Traumatic haemorrhage Diseases 0.000 claims abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 3
- 201000001119 neuropathy Diseases 0.000 claims abstract description 3
- 230000007823 neuropathy Effects 0.000 claims abstract description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims abstract description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims abstract description 3
- 230000000472 traumatic effect Effects 0.000 claims abstract description 3
- 208000035143 Bacterial infection Diseases 0.000 claims abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 230000035935 pregnancy Effects 0.000 claims abstract 2
- 208000031354 Hyphema Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims 1
- 239000002689 soil Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 description 25
- 230000008733 trauma Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 230000010410 reperfusion Effects 0.000 description 21
- 206010063897 Renal ischaemia Diseases 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 230000037361 pathway Effects 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 230000002685 pulmonary effect Effects 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 210000000265 leukocyte Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000003945 NF-kappa B Human genes 0.000 description 8
- 108010057466 NF-kappa B Proteins 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 5
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000008817 pulmonary damage Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000003467 diminishing effect Effects 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000001502 melanotroph Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 230000002267 hypothalamic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000030090 Acute Disease Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 206010001053 acute respiratory failure Diseases 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000025698 brain inflammatory disease Diseases 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010061688 Barotrauma Diseases 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010051288 Central nervous system inflammation Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100039919 Intercellular adhesion molecule 5 Human genes 0.000 description 1
- 101710148796 Intercellular adhesion molecule 5 Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010025102 Lung infiltration Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 229940089960 chloroacetate Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000003532 endogenous pyrogen Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000001756 lactotroph Anatomy 0.000 description 1
- 230000001381 lactotroph Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- PWDYHMBTPGXCSN-VCBMUGGBSA-N n,n'-bis[3,5-bis[(e)-n-(diaminomethylideneamino)-c-methylcarbonimidoyl]phenyl]decanediamide Chemical compound NC(N)=N/N=C(\C)C1=CC(C(=N/N=C(N)N)/C)=CC(NC(=O)CCCCCCCCC(=O)NC=2C=C(C=C(C=2)C(\C)=N\N=C(N)N)C(\C)=N\N=C(N)N)=C1 PWDYHMBTPGXCSN-VCBMUGGBSA-N 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000001067 neuroprotector Effects 0.000 description 1
- 239000003367 nicotinic antagonist Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2006/000031 WO2007129879A1 (es) | 2006-05-08 | 2006-05-08 | EL USO DE LA NICOTINA, SUS ANÁLOGOS, SUS PRECURSORES O SUS DERIVADOS EN EL TRATAMIENTO DE DIVERSOS PROCESOS PATOLÓGICOS SUSCEPTIBLES DE MEJORAR CON α-MSH ADMINISTRADA EN FORMA PROFILÁCTICA O TERAPÉUTICA. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ572366A true NZ572366A (en) | 2012-02-24 |
Family
ID=38667940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ572366A NZ572366A (en) | 2006-05-08 | 2006-05-08 | THE USE OF NICOTINE, ANALOGUES THEREOF, PRECURSORS THEREOF OR DERIVATIVES THEREOF IN THE TREATMENT OF VARIOUS PATHOLOGICAL PROCESSES CAPABLE OF IMPROVEMENT WITH a-MSH ADMINISTERED IN PROPHYLACTIC OR THERAPEUTIC FORM |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20090197921A1 (https=) |
| EP (4) | EP2027860A1 (https=) |
| JP (1) | JP2009536193A (https=) |
| KR (1) | KR20130116374A (https=) |
| CN (1) | CN101437515B (https=) |
| AU (1) | AU2006343439B2 (https=) |
| BR (1) | BRPI0621650A2 (https=) |
| CA (1) | CA2651580C (https=) |
| DK (1) | DK2801360T3 (https=) |
| ES (1) | ES2683323T3 (https=) |
| MX (1) | MX2008011473A (https=) |
| NZ (1) | NZ572366A (https=) |
| WO (1) | WO2007129879A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10639300B2 (en) | 2016-04-12 | 2020-05-05 | Arturo Solis Herrera | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
| US20110206642A1 (en) * | 2009-10-15 | 2011-08-25 | Cohava Gelber | Preventing obesity-related metabolic syndrome with melagonesis |
| US9668969B1 (en) | 2012-02-22 | 2017-06-06 | Arturo Solis Herrera | Methods of using QIAPINE |
| KR20170043655A (ko) | 2014-09-09 | 2017-04-21 | 아르투로 솔리스 헤레라 | 멜라닌 및 멜라닌 유사체, 전구체, 및 유도체로 안과 질병, 질환, 및 증상의 치료 및 예방을 위한 방법 |
| LU101520B1 (en) * | 2019-12-02 | 2021-06-07 | Herrera Arturo Solis | (S)-3-[1-Methylpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a homogeneous, viscous, semi-solid topical medication and topical medication |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
| US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| CA2341952A1 (en) * | 2001-03-23 | 2002-09-23 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| US8729129B2 (en) * | 2004-03-25 | 2014-05-20 | The Feinstein Institute For Medical Research | Neural tourniquet |
-
2006
- 2006-05-08 NZ NZ572366A patent/NZ572366A/en not_active IP Right Cessation
- 2006-05-08 ES ES14170573.1T patent/ES2683323T3/es active Active
- 2006-05-08 KR KR1020137025038A patent/KR20130116374A/ko not_active Withdrawn
- 2006-05-08 AU AU2006343439A patent/AU2006343439B2/en active Active
- 2006-05-08 CA CA2651580A patent/CA2651580C/en active Active
- 2006-05-08 WO PCT/MX2006/000031 patent/WO2007129879A1/es not_active Ceased
- 2006-05-08 EP EP06747531A patent/EP2027860A1/en not_active Ceased
- 2006-05-08 JP JP2009509455A patent/JP2009536193A/ja active Pending
- 2006-05-08 EP EP14170573.1A patent/EP2801360B1/en active Active
- 2006-05-08 CN CN200680054519.1A patent/CN101437515B/zh not_active Expired - Fee Related
- 2006-05-08 EP EP14170571.5A patent/EP2801358A3/en not_active Withdrawn
- 2006-05-08 BR BRPI0621650-1A patent/BRPI0621650A2/pt not_active Application Discontinuation
- 2006-05-08 DK DK14170573.1T patent/DK2801360T3/en active
- 2006-05-08 EP EP20140170572 patent/EP2801359A3/en not_active Withdrawn
-
2008
- 2008-09-08 MX MX2008011473A patent/MX2008011473A/es active IP Right Grant
-
2009
- 2009-04-06 US US12/418,993 patent/US20090197921A1/en not_active Abandoned
-
2012
- 2012-06-27 US US13/534,710 patent/US20120270907A1/en not_active Abandoned
-
2015
- 2015-09-22 US US14/860,973 patent/US20160008347A1/en not_active Abandoned
-
2016
- 2016-06-08 US US15/176,555 patent/US20160279116A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10639300B2 (en) | 2016-04-12 | 2020-05-05 | Arturo Solis Herrera | Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101437515B (zh) | 2016-04-20 |
| WO2007129879A1 (es) | 2007-11-15 |
| ES2683323T3 (es) | 2018-09-26 |
| US20160008347A1 (en) | 2016-01-14 |
| DK2801360T3 (en) | 2018-07-23 |
| US20090197921A1 (en) | 2009-08-06 |
| AU2006343439B2 (en) | 2013-05-16 |
| EP2801358A2 (en) | 2014-11-12 |
| EP2801360B1 (en) | 2018-04-25 |
| EP2801358A3 (en) | 2015-03-04 |
| KR20130116374A (ko) | 2013-10-23 |
| CN101437515A (zh) | 2009-05-20 |
| EP2027860A1 (en) | 2009-02-25 |
| JP2009536193A (ja) | 2009-10-08 |
| US20120270907A1 (en) | 2012-10-25 |
| EP2801359A3 (en) | 2015-05-06 |
| EP2801360A2 (en) | 2014-11-12 |
| BRPI0621650A2 (pt) | 2011-12-20 |
| EP2801360A3 (en) | 2015-03-04 |
| CA2651580C (en) | 2016-01-19 |
| AU2006343439A1 (en) | 2007-11-15 |
| EP2801359A2 (en) | 2014-11-12 |
| CA2651580A1 (en) | 2007-11-15 |
| MX2008011473A (es) | 2008-09-24 |
| US20160279116A1 (en) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Olson et al. | Intraputaminal infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one-year follow-up of first clinical trial | |
| US20160279116A1 (en) | Therapeutic uses of nicotine | |
| JPH04502017A (ja) | 小ペプチド類の安定化水系調剤 | |
| WO2000040086A1 (en) | Formulations for treating disease and methods of using same | |
| US20100324327A1 (en) | Novel use of dimethylfumarate | |
| BRPI0719816B1 (pt) | Uso do fator de crescimento epidérmico (egf) humano para preparar uma composição farmacêutica injetável para a restauração morfofuncional de nervos periféricos em neuropatia diabética e a referida composição | |
| CN113577083B (zh) | 一种小分子化合物组合在制备预防和治疗视网膜损伤性疾病药物中的应用 | |
| Goyagi et al. | Neuroprotective effects of selective beta-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; a dose–response study | |
| CN106434806B (zh) | 蛹虫草多肽及其制备方法和应用 | |
| RU2727142C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| JPH02117698A (ja) | 血管内皮細胞成長因子 | |
| RU2442584C2 (ru) | ИСПОЛЬЗОВАНИЕ НИКОТИНА, ЕГО АНАЛОГОВ, ПРЕДШЕСТВЕННИКОВ И ПРОИЗВОДНЫХ ПРИ ЛЕЧЕНИИ РАЗЛИЧНЫХ ПАТОЛОГИЧЕСКИХ ПРОЦЕССОВ, ПОДДАЮЩИХСЯ ЛЕЧЕНИЮ, ПУТЕМ ВВЕДЕНИЯ α-MSH ДЛЯ ПРОФИЛАКТИЧЕСКИХ ИЛИ ТЕРАПЕВТИЧЕСКИХ ЦЕЛЕЙ | |
| Walter | Clinical impressions on treatment of obsessional states with intravenous clomipramine (Anafranil) | |
| CN111529526A (zh) | 一种化合物在制备治疗急性胰腺炎的药物中的用途 | |
| KR20090006069A (ko) | 예방적 또는 치료적 형태로 투여된 α-ＭＳＨ를 사용하여 개선시킬 수 있는 다양한 병리 과정을 치료하기 위한 니코틴, 그의 유사체, 그의 전구체 또는 그의 유도체의 용도 | |
| EP4487698A1 (en) | A micronutrient composition to prevent and reverse protein glycation during oxidative stress in human | |
| WO2025256277A1 (zh) | 黑素细胞刺激素α-MSH在治疗肝癌中的应用 | |
| CN108434160A (zh) | N-乙酰-d-氨基葡萄糖盐在制备防治失眠药物及保健品中的应用及药物 | |
| CN115300511A (zh) | 一种组合物的医药用途 | |
| CN114831990A (zh) | 青藤碱在制备治疗帕金森病药物组合物中的应用 | |
| WO2002045719A1 (fr) | Remedes destines au symptome de type hibernation et agents induisant le symptome de type hibernation ou remediant a ce symptome | |
| JP2020059691A (ja) | ヒドロキシアニゴルホンの使用 | |
| JP2010222289A (ja) | 細胞死を予防するための医薬剤 | |
| JP2003300902A (ja) | 血管新生阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 MAY 2016 BY HALFORDS IP Effective date: 20130423 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 MAY 2017 BY HALFORDS IP Effective date: 20160322 |
|
| S43A | Offer to surrender | ||
| S43 | Surrender of patents according section 43 patents act |
Effective date: 20160629 |